Pacira BioSciences to Participate in Fireside Chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference

Rhea-AI Summary

TAMPA, Fla., Aug. 02, 2022 – Pacira BioSciences (NASDAQ: PCRX) will participate in the analyst-led fireside chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference on Aug. 10, 2022, at 11:30 AM ET. Investors can access the live audio on the company’s website, with a replay available for two weeks post-event. Pacira is focused on non-opioid treatments, marketing products like EXPAREL®, ZILRETTA®, and ioveraº®. The company's mission aims to redefine opioid use, addressing chronic pain and related conditions.

News Market Reaction – PCRX

-0.36%

-0.36% Session move

In the trading session that priced this news, PCRX declined 0.36%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TAMPA, Fla., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference at 11:30 AM ET on Wednesday, August 10, 2022. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

About Pacira         

Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. Pacira has three commercial-stage non-opioid treatments: EXPAREL^® (bupivacaine liposome injectable suspension), a long-acting, local analgesia currently approved for postsurgical pain management; ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain; and ioveraº^®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.

FAQ

When is Pacira BioSciences participating in the Wedbush PacGrow Healthcare Virtual Conference?

Pacira BioSciences will participate in the conference on August 10, 2022, at 11:30 AM ET.

How can I access the live audio of Pacira's conference participation?

The live audio can be accessed by visiting the 'Events' page on Pacira's website.

What are the main products offered by Pacira BioSciences?

Pacira offers non-opioid treatments such as EXPAREL®, ZILRETTA®, and ioveraº®.

What is Pacira's mission regarding opioid use?

Pacira's mission is to provide non-opioid options and redefine opioids as rescue therapy only.

Will there be a replay available for the Pacira conference?

Yes, a replay of the webcast will be available for two weeks following the event.